

07/07/05

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/800,240
				Filing Date	March 6, 2001
				First Named Inventor	Peter PREVELIGE, Jr.
				Art Unit	1648
Sheet	1	of	1	Examiner Name	Jeffrey S. Parkin
				Attorney Docket Number	057909-11000

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>2</sup> Kind Code <sup>2</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Carolyn M. TESCHKE et al., Inhibition of Viral Capsid Assembly by 1,1'-Bi(4-anilinonaphthalene-5-sulfonic Acid), Biochemistry 1993, 10658-10665, Vol. 32, No. 40.	



Examiner Signature	Date Considered	02/04/07
-----------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

08/26/04

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				09/800,240		
				Filing Date		
				March, 6, 2001		
				First Named Inventor		
				Peter PREVELIGE, Jr.		
				Art Unit		
				1648		
				Examiner Name		
				Jeffrey S. PARKIN		
				Attorney Docket Number		
				057909-011000		
Sheet	1	of	3			

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-5,716,613 A	February 10, 1998	Guber et al.	
	2	US-5,789,245 A	August 4, 1998	Dubensky et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					T <sup>2</sup>
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
J	3	EHRlich ET AL., "ASSEMBLY OF RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CAPSID PROTEIN IN VITRO, JOURNAL OF VIROLOGY," VOL. 66, p. 4874-4883 (1992)			
	4	COLIGAN ET AL., "STRATEGIES OF PROTEIN PURIFICATION AND CHARACTERIZATION", CURRENT PROTOCOLS IN PROTEIN SCIENCE, 1.1.1-1.3.7 (1995)			
	5	GROSS ET AL., "IN VITRO ASSEMBLY PROPERTIES OF PURIFIED BACTERIALLY EXPRESSED CAPSID PROTEINS OF HUMAN IMMUNODEFICIENCY VIRUS", EUROPEAN JOURNAL OF BIOCHEMISTRY, VOL. 249, PP. 592-600 (1997)			
	6	GROSS ET AL., "A CONFORMATIONAL SWITCH CONTROLLING HIV-1 MORPHOGENESIS", THE EUROPEAN MOLECULAR BIOLOGY ORGANIZATION JOURNAL, VOL. 19, NO. 1, PP. 103-113 (2000)			

Examiner Signature		Date Considered	02/05/07
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		09/800,240	
				Filing Date		March, 6, 2001	
				First Named Inventor		Peter PREVELIGE, Jr.	
				Group Art Unit		1648	
				Examiner Name		Jeffrey S. PARKIN	
Sheet	2	of	3	Attorney Docket Number		057909-011000	

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	7	HARRISON ET AL., "CHAPTER 3: VIRUS STRUCTURE", FIELDS VIROLOGY, THIRD EDITION, PP. 59-99 (1996)	
	8	KNEJZLIK ET AL., "ISOLATION AND CHARACTERIZATION OF THE MASON-PFIZER MONKEY VIRUS p12 PROTEIN", VIROLOGY, VOL. 324, PP. 204-212 (2004)	
	9	MURPHY, "CHAPTER 2: VIRUS TAXONOMY", FIELDS VIROLOGY, THIRD EDITION, PP. 15-57 (1996)	
	10	PREVELIGE ET AL., "SCAFFOLDING PROTEIN REGULATES THE POLYMERIZATION OF P22 COAT SUBUNITS INTO ICOSAEDRAL SHELLS IN VITRO", JOURNAL OF MOLECULAR BIOLOGY, VOL. 202, PP. 743-757 (1988)	
	11	PREVELIGE ET AL., "NUCLEATION AND GROWTH PHASES IN THE POLYMERIZATION OF COAT AND SCAFFOLDING SUBUNITS INTO ICOSAEDRAL PROCAPSID SHELLS", BIOPHYSICAL JOURNAL, VOL. 64, PP. 824-835 (1993)	
	12	PREVELIGE ET AL., "INHIBITING VIRUS-CAPSID ASSEMBLY BY ALTERING THE POLYMERISATION PATHWAY", TIBTECH, VOL. 16, PP. 66165 (1998)	
	13	SPECTOR ET AL., "THE POST-POLIO SYNDROME: CURRENT CONCEPTS AND TREATMENT", INFECTIONS IN MEDICINE, PP. 462-478 (1997)	

Examiner Signature		Date Considered	02/05/07
-----------------------	--	--------------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				09/800,240	
				Filing Date	
				March, 6, 2001	
				First Named Inventor	
				Peter PREVELIGE, Jr.	
Group Art Unit		1648			
Examiner Name		Jeffrey S. PARKIN			
Attorney Docket Number		057909-011000			
Sheet	3	of	3		

2	14	TANG ET AL., "ANTIVIRAL INHIBITION OF THE HIV-1 CAPSID PROTEIN," J. MOL. BIOL. 327, 1013-1020 (2003)	
↓	15	TRONO ET AL., "HIV-1 GAG MUTANTS CAN DOMINANTLY INTERFERE WITH THE REPLICATION OF THE WILD-TYPE VIRUS", CELL, VOL. 59, PP. 113-120 (1989)	
↓	16	VLASUK ET AL., "PURIFICATION AND CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) CORE PRECURSOR (p55) EXPRESSED IN SACCHAROMYCES CEREVISIAE", THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 264, NO. 20, ISSUE OF JULY 15, PP. 12106-12112 (1989)	

Examiner Signature		Date Considered	02/05/07
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.